Pacer Advisors
PCVX icon

Pacer Advisors’s Vaxcyte PCVX Stock Holding History

Pacer Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-539
Closed -$40.7K – 2658
2024
Q2 		$40.7K Sell
539
-50
-8% -$3.4K ﹤0.01% 3265
2024
Q1 		$40.2K Buy
+589
New +$40.8K ﹤0.01% 3259
2021
Q2 		– Sell
-2,122
Closed -$42K – 1510
2021
Q1 		$42K Buy
2,122
+850
+67% +$21.4K ﹤0.01% 1459
2020
Q4 		$34K Buy
+1,272
New +$47.3K ﹤0.01% 1452

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors's PCVX Position: Q3 2024 in Review

Pacer Advisors sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 539 shares — an estimated $40.7K sold.

Pacer Advisors first reported a position in PCVX in Q4 2020 and held it in 4 quarters. The position peaked at $42K in Q1 2021. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • Pacer Advisors reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 539 Vaxcyte shares in Q3 2024, an estimated $40.7K.
  • Pacer Advisors first reported a position in Vaxcyte in Q4 2020 and held it in 4 quarters.
  • Pacer Advisors's Vaxcyte position peaked at $42K in Q1 2021.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.